Monitor for any further stake changes or conversion to a 13D filing, though T. Rowe Price's passive certification makes activist intent unlikely. The increase is consistent with normal portfolio rebalancing.
XENE drugs
XENE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $39.17entry
- T+1 · 8d ago +3.27%α +0.90% · $40.45
- T+5 · 4d ago +3.34%α +0.75% · $40.48
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
T. Rowe Price Investment Management filed an amended Schedule 13G reporting a 10.3% passive stake in Xenon Pharmaceuticals as of October 31, 2026, up from 8.2% as of September 30, 2026. The increase of approximately 2.1 percentage points (about 2 million shares) is a routine passive institutional adjustment with no directional signal.
Key Financial Metrics
Key Facts
- T. Rowe Price Investment Management reported beneficial ownership of 9,996,124 shares of Xenon Pharmaceuticals common stock as of October 31, 2026
- Stake represents 10.3% of outstanding shares, up from 8.2% (7,905,757 shares) as of September 30, 2026
- The filing is a routine quarterly update by a passive institutional investor under Rule 13d-1(b)
- The investor certifies shares were acquired and held in the ordinary course of business, not to influence control
Financial Impact
Increase of approximately 2.09 million shares, valued at roughly $80M based on $3.8B market cap and 10.3% stake
Risk Factors
- No material risks identified from this passive stake amendment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001897612-26-000704 |
| Document: 0001897612-26-000704-index.html | 0001897612-26-000704 |
| Document: 0001897612-26-000704.txt | 0001897612-26-000704 |
Track record
19 reports on XENE
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Viewing Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
- Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
- Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
- Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers